Literature DB >> 35516715

Post-COVID-19 pulmonary cavitation and tension pneumothorax in a non-ventilated patient.

Bhagya Vardhan1, Payel Biswas2, Subhankar Chatterjee1, Sudhanshu Mishra3, Surendra Baskey4, Umesh K Ojha1.   

Abstract

Cavitation and pneumothorax are independently associated with high morbidity and mortality in coronavirus disease-2019 (COVID-19). While spontaneous (non-traumatic) pneumothorax formation has commonly been observed among mechanically ventilated COVID-19 patients, there are few rare reports of COVID-19 associated pneumothorax without any history of barotrauma and other conventional risk factors. Here, we report a unique case of post-COVID-19 cavitation and tension pneumothorax which was further complicated by hydropneumothorax formation in a young patient who suffered severe COVID-19 pneumonia 4 weeks back. As the patient was devoid of any conventional risk factors, we believe that persistent inflammatory alveolar damage even after clinical recovery from COVID-19 played a key role in pulmonary cavitation followed by pneumothorax formation. With prompt clinical and radiological recognition of these fatal, yet treatable complications of COVID-19 pneumonia, the patient was saved and had an uneventful recovery. Copyright:
© 2022 Journal of Family Medicine and Primary Care.

Entities:  

Keywords:  COVID-19; hydropneumothorax; lung cavitation; pneumothorax; post-covid complications

Year:  2022        PMID: 35516715      PMCID: PMC9067220          DOI: 10.4103/jfmpc.jfmpc_1455_21

Source DB:  PubMed          Journal:  J Family Med Prim Care        ISSN: 2249-4863


Introduction

Pneumothorax is the accumulation of air within the pleural space and can be classified into two types: traumatic and spontaneous (primary or secondary). Secondary spontaneous pneumothorax (SSP) develops in association with an already diseased lung; whereas primary spontaneous pneumothorax (PSP) happens in patients without a history of associated pulmonary pathologies.[1] While coronavirus disease-2019 (COVID-19) can result in a plethora of pulmonary and non-pulmonary complications, pneumothorax and cavity formation are relatively uncommon, yet carry fatal outcomes.[123] Two retrospective analyses showed the occurrence of pneumothorax in 1–2% of COVID-19 patients who almost invariably required hospitalization and management in the intensive care unit.[45] The patients who required positive pressure ventilation (PPV) showed a relatively higher incidence of spontaneous pneumothorax, as high as 15%.[6] Multiple cases of PSP have also been reported in non-intubated patients and/or patients with no prior lung diseases and even as an initial presentation of worsening lung function due to COVID-19 pneumonia, albeit the underlying mechanism and impact of this association remain uncertain.[78] However, tension pneumothorax is an extremely rare but life-threatening complication of COVID-19 pneumonia and only a handful of cases have been reported to date.[91011121314] Herein, we report a rare case of severe post-COVID-19 pulmonary cavitation and tension PSP which was further complicated by hydropneumothorax formation in a patient without any associated lung disease or prior exposure to PPV.

Case Report

A 28-year-old (non-vaccinated against COVID-19), non-smoker, overweight male without any other comorbidity presented to the emergency with complaints of cough and chest pain for 3 days and sudden onset shortness of breath (SOB) for 1 day. He was admitted to the same institute 6 weeks back with the diagnosis of severe COVID-19 pneumonia [COVID-19 Reporting and Data System (CORADS)-6, computed tomography severity score (CTSS)- 20/25] [Figure 1a]. He was treated as per standard national guideline,[15] required no ventilator support, and discharged 4 weeks back with a stable hemodynamic state and SpO2 >94% for 3 days without oxygen support. He was doing well at home for 4 weeks until he developed sudden onset of SOB while taking inhalational budesonide (prescribed on discharge).
Figure 1

(a): Predominantly peripheral ground glass opacities with interlobular septal thickening, consolidative lesions and subpleural fibrotic changes in both lungs, most marked in bilateral posterobasal distribution, features highly suggestive of COVID-19 pneumonia. (b): Chest X-ray postero-anterior view shows left sided large tension pneumothorax with collapsed lung and significant right-shift of the mediastinal structures. The right lung also shows patchy non-homogenous opacities more in the middle and lower zones, suggestive of pneumonitic changes. (c): Chest X-ray postero-anterior view after intercostals drainage (ICD) insertion shows significant re-expansion of the left lung with residual apical pneumothorax, and possibility of a loculated hydropneumothorax in the left lower zone with patchy non-hompgenous opacities scattered in both lungs. Note are also made of the ICD appropriately stationed on left side and subcutaneous emphysema over left chest wall. (d): Predominantly peripheral ground glass opacities with interlobular septal thickening, consolidative lesions and subpleural fibrotic changes in both lungs, a thick-walled cavitary lesion (4 cm × 2.3 cm × 5.4 cm) with air-fluid level within in the left lower lobe and loculated hydropnemothorax in left lung with chest tube in situ

(a): Predominantly peripheral ground glass opacities with interlobular septal thickening, consolidative lesions and subpleural fibrotic changes in both lungs, most marked in bilateral posterobasal distribution, features highly suggestive of COVID-19 pneumonia. (b): Chest X-ray postero-anterior view shows left sided large tension pneumothorax with collapsed lung and significant right-shift of the mediastinal structures. The right lung also shows patchy non-homogenous opacities more in the middle and lower zones, suggestive of pneumonitic changes. (c): Chest X-ray postero-anterior view after intercostals drainage (ICD) insertion shows significant re-expansion of the left lung with residual apical pneumothorax, and possibility of a loculated hydropneumothorax in the left lower zone with patchy non-hompgenous opacities scattered in both lungs. Note are also made of the ICD appropriately stationed on left side and subcutaneous emphysema over left chest wall. (d): Predominantly peripheral ground glass opacities with interlobular septal thickening, consolidative lesions and subpleural fibrotic changes in both lungs, a thick-walled cavitary lesion (4 cm × 2.3 cm × 5.4 cm) with air-fluid level within in the left lower lobe and loculated hydropnemothorax in left lung with chest tube in situ On physical examination, he was conscious, alert, oriented, restless, and dyspneic. His SpO2 was 56% (room air), BP 110/70 mm Hg, and pulse 158 beats/min. Breathing sound was diminished on the left side. On percussion, there was hyper-resonant note on the left side of the chest as compared to the right side. Examination of other systems did not show any abnormality clinically. About 100% oxygen supply and nebulization with bronchodilators and inhalational steroids were started. Urgent chest X-ray (CXR) was done and revealed tension pneumothorax on the left side [Figure 1b]. Water-sealed intercostal chest drainage (ICD) was performed on an emergency basis and thereafter patient’s symptoms, clinical parameters improved markedly (SpO2-98% with 2 L/min O2) with a radiological resolution of pneumothorax [Figure 1c]. High-resolution computed tomography (HRCT) scan of chest depicted predominantly peripheral ground glass opacities with consolidative lesions and subpleural fibrotic changes in both lungs, a cavitary lesion (with air-fluid level within) in left lower lobe and left hydropneumothorax with CTSS 25/25 [Figure 1d]. On laboratory examination, his reports showed complete hemogram, liver and renal function tests, serum electrolytes, lipid profile, blood glucose, ferritin, procalcitonin, and urine routine examination to be normal. C-reactive protein, anti-nuclear antibody, and anti-neutrophil cytoplasmic antibody were negative. D-dimer and interleukin-6 were 0.56 mcg/ml (n,<0.5) and 56.84 pg/ml (n,<7), respectively. Sputum for acid-fast bacilli and cartridge-based nucleic acid amplification test was negative. The reverse transcription–polymerase chain reaction report for COVID-19 was negative. He was treated with moist oxygen, broad spectrum antibiotics (piperacillin–tazobactum and levofloxacin), inj. tramadol and paracetamol (for pain), montelukast, levocetirizine, N-acetylcysteine, acebrophylline (as a cough suppressant and mucociliary clearance), pirferiodne (anti-fibrotic), salbutamol and budesonide nebulization (as bronchodilator and anti-inflammatory), and chest physiotherapy. As there was a radiological resolution of pneumothorax and no fluctuation in the fluid column of the tube and, ICD was removed after 6 days. The patient was asymptomatic and could maintain SpO2 of 98–100% on room air for 3 days before discharge with further planning to referral to a higher centre for consideration of lung transplantation.

Discussion

Pneumothorax can occur in any phase and at any point during the course of illness (as long as after several weeks of apparent recovery) irrespective of the severity of the COVID-19 infection.[1617] Pneumothorax occurred in our patient 4 weeks later (from the time of discharge during the initial attack of COVID-19), considering it to be a late sequel. His rapidly deteriorating SpO2 level compelled us to go for immediate ICD insertion as a working diagnosis of tension pneumothorax had been made by the CXR findings. HRCT, which was performed three days after ICD insertion, showed a thick-walled cavitary lesion in the lower lobe of the left lung as well as left-sided hydropneumothorax. His initial CTSS during first-time hospital admission was 20/25 suggestive of severe COVID-19, and this time CTSS was 25/25 implying further extensive progression of the disease even after discharge. The cavity may be attributed to post-COVID changes as there was no evidence of any cavity in the previous HRCT scan and the possibility of co-existent mycobacterial, fungal, and autoimmune diseases were ruled out by appropriate tests. Post-COVID cavitation may also be due to direct alveolar damage by excess cytokine release and as a result of infarct caused by microthrombi formation.[23] Although unlikely from the clinical point of view, the coexistent pulmonary thromboembolism could not be ruled out in our patient due to the non-availability of CT pulmonary angiography in this set-up.[10] The presence of subpleural bullae/mini-blebs and pneumatocele has been most popularly discussed as the cause of PSP in general. Patients with a history of smoking, prolonged cough, pre-existing lung pathology, connective tissue disorder, tall stature, and male gender, in particular, are at risk.[18] Pneumothorax can rarely occur as a complication of acute respiratory distress syndrome (ARDS) too with the possible mechanism being alveolar rupture due to barotrauma or pressure-overload following induced ventilation.[12] Rarely spontaneous tension pneumothorax can occur in association with COVID-19 without any history of prior PPV.[914] Some researchers suggested that chronic cystic changes in the lung may be caused by a spectrum of severe COVID-19 itself, which later on may lead to the development of pneumothorax after getting ruptured by the greater force of cough due to greater lung damage.[919] Zoumot et al.[3] also noted severe morbidity and mortality in patients presented with post-COVID-19 lung cavitation irrespective of the presence of pneumothorax; they have also hypothesized that cavitary lesions can heighten the risk of pneumothorax by extending themselves to the pleura and rupture of the cavity wall. Surprisingly, our patient had no known risk factor except being male and no obvious subpleural bulla/bleb or cystic changes were evident on HRCT chest at any point during the whole course of his illness. Therefore, the development of spontaneous pneumothorax, in this case, was most likely due to structural lung damages resultant of COVID-19-induced inflammatory injury (as evidenced by persistent high serum concentration of interleukin-6) and rupture of the cavity. Development of hydropneumothorax (which was not evident in CXR, but later unfurled in HRCT) was probably the result of ICD insertion.[19]

Conclusion

Although ARDS appears to be the prime suspect as a cause of rapid deterioration of SpO2 in COVID-19, recognition of uncommon, fatal but potentially curable etiology like tension pneumothorax is crucial for the management of such cases. Misdiagnosis can lead to protocol-based initiation of PPV and the outcome may be detrimental with underlying unrecognized pneumothoraces.[11] Cavitation, primary spontaneous tension pneumothorax complicated by hydropneumothorax in a post-COVID patient without any history of mechanical ventilation, and other conventional risk factors made this index case unique. Moreover, our patient was saved by prompt recognition of the condition by astute physical examination and immediate radiography and appropriate multidisciplinary management in time even in a resource-constrained setup.

Informed consent

Written consent has been taken for using the medical data of the patient for academic purposes while maintaining full anonymity.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  19 in total

Review 1.  Review: Diagnosis and treatment of primary spontaneous pneumothorax.

Authors:  Shi-ping Luh
Journal:  J Zhejiang Univ Sci B       Date:  2010-10       Impact factor: 3.066

2.  Pneumomediastinum and spontaneous pneumothorax as an extrapulmonary complication of COVID-19 disease.

Authors:  Jesse Mauricio López Vega; María Luz Parra Gordo; Aurea Diez Tascón; Silvia Ossaba Vélez
Journal:  Emerg Radiol       Date:  2020-06-11

3.  COVID-19 and pneumothorax: a multicentre retrospective case series.

Authors:  Anthony W Martinelli; Tejas Ingle; Joseph Newman; Iftikhar Nadeem; Karl Jackson; Nicholas D Lane; James Melhorn; Helen E Davies; Anthony J Rostron; Aldrin Adeni; Kevin Conroy; Nick Woznitza; Matthew Matson; Simon E Brill; James Murray; Amar Shah; Revati Naran; Samanjit S Hare; Oliver Collas; Sarah Bigham; Michael Spiro; Margaret M Huang; Beenish Iqbal; Sarah Trenfield; Stephane Ledot; Sujal Desai; Lewis Standing; Judith Babar; Razeen Mahroof; Ian Smith; Kai Lee; Nairi Tchrakian; Stephanie Uys; William Ricketts; Anant R C Patel; Avinash Aujayeb; Maria Kokosi; Alexander J K Wilkinson; Stefan J Marciniak
Journal:  Eur Respir J       Date:  2020-11-19       Impact factor: 16.671

4.  Tension pneumothorax in patient with COVID-19 infection.

Authors:  Ali Vahidirad; Ali Jangjoo; Mohadeseh Ghelichli; Ali Arian Nia; Tooraj Zandbaf
Journal:  Radiol Case Rep       Date:  2020-12-02

5.  Pneumothorax in patients with prior or current COVID-19 pneumonia.

Authors:  Matthijs L Janssen; Mirjam J G van Manen; Sander E Cretier; Gert-Jan Braunstahl
Journal:  Respir Med Case Rep       Date:  2020-08-13

6.  Spontaneous tension pneumothorax and acute pulmonary emboli in a patient with COVID-19 infection.

Authors:  Ruhaid Khurram; Franklin T F Johnson; Revati Naran; Samanjit Hare
Journal:  BMJ Case Rep       Date:  2020-08-11

7.  Delayed recurrent spontaneous pneumothorax in a patient recovering from COVID-19 pneumonia.

Authors:  Viraj Shah; Katie Brill; Gunmeet Dhingra; Santhana Kannan
Journal:  Korean J Anesthesiol       Date:  2020-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.